roginolisib

Phase 2Small molecule

IiOnctura

roginolisib is one of 160 small molecule programs targeting Myelofibrosis，MF. It is currently in Phase 2.

Indications

Total Trials

Active Trials

159

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myelofibrosis，mfRecruiting

Uveal MelanomaActive, not recruiting

Lung CancerActive, not recruiting

LymphomaRecruiting

Chronic Lymphocytic LeukemiaRecruiting

Myelofibrosis，mfPreclinical

Recruiting

Uveal MelanomaPhase 2

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

LymphomaPhase 2

Recruiting

Chronic Lymphocytic LeukemiaPhase 2

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

roginolisib

IiOnctura

Phase 2

1 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Active, not recruiting

Lung Cancer

NCT06879717

Q3 2028

PreclinicalRecruiting

Myelofibrosis，mf

NCT06887803

Q4 2028

Phase 2Active, not recruiting

Uveal Melanoma

NCT06717126

Q4 2029

Phase 1Recruiting

Uveal Melanoma

NCT07203391

Clinical

Trials by Indication[1]

Uveal Melanoma2 trials

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

Active, not recruiting·IiOnctura·Phase 2·NCT06717126·85 enrolled

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

Recruiting·SSt Vincent's Hospital, Sydney·Phase 1·NCT07203391·8 enrolled

Lymphoma1 trial

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 1/2·NCT07018752·49 enrolled

Lung Cancer1 trial

A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients

Active, not recruiting·IiOnctura·Phase 1/2·NCT06879717·45 enrolled

Chronic Lymphocytic Leukemia1 trial

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Recruiting·—·Phase 1/2·NCT06644183·64 enrolled

Myelofibrosis，MF1 trial

A Phase I/II Open-Label, Multi-centre Study to Assess the Safety and Tolerability of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to an Approved JAK Inhibitors (HEMA-MED)

Recruiting·IiOnctura·Preclinical·NCT06887803·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for roginolisib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — roginolisib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for roginolisib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — iOnctura company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IiOnctura

roginolisib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2028

Q4 2028

Q4 2029

Trials by Indication[1]

Uveal Melanoma2 trials

Lymphoma1 trial

Lung Cancer1 trial

Chronic Lymphocytic Leukemia1 trial

Myelofibrosis，MF1 trial

References

Drug Info

Quick Facts

Related News